Theranexus (XPAR:ALTHX) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus COGS-to-Revenue?

Theranexus's Cost of Goods Sold for the six months ended in Dec. 2023 was €2.58 Mil. Its Revenue for the six months ended in Dec. 2023 was €0.00 Mil.

Theranexus's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Theranexus's Gross Margin % for the six months ended in Dec. 2023 was %.

Theranexus COGS-to-Revenue Historical Data

The historical data trend for Theranexus's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus COGS-to-Revenue Chart

Theranexus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Theranexus Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Theranexus COGS-to-Revenue Calculation

Theranexus's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5.038	/	0
	=

Theranexus's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.581	/	0
	=

Theranexus (XPAR:ALTHX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Theranexus's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.581 / 0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Theranexus COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theranexus's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus (XPAR:ALTHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines